Ovomet® - Clinical Research Data Summary
Ovomet® Eggshell Membrane Joint Support Ingredient
Ovomet® is a clinically studied ingredient used in the following Silver Fern™ Brand product:
- Joint Complex – https://www.silverfernbrand.com/products/joint-complex
Introduction
Clinical research on Ovomet® eggshell membrane includes multiple human trials in older adults, physically active individuals, and participants experiencing joint discomfort, consistently using a 300 mg daily dose over 30–50 days. These studies — including randomized, double-blind, placebo-controlled trials — have reported improvements in measures of joint comfort, stiffness, and physical function, with some studies observing changes as early as three days and continued improvements through day 50. In certain study measures, some study measures showed improvements in joint comfort scores of approximately 40–52%. Ovomet® has also been associated with objective biomechanical changes, including maintenance or increases in Achilles tendon stiffness in both older and active populations. Collectively, these findings suggest that Ovomet® may help support joint comfort, mobility, and connective tissue health across a range of age groups and activity levels.*
Preclinical research on eggshell membrane further suggests potential mechanisms supporting connective tissue health. Studies in cellular models have demonstrated modulation of signaling pathways associated with inflammation, including effects on cytokines such as TNF-α, IL-1β, and IL-6 as well as NF-κB activity. In animal models of joint stress, eggshell membrane supplementation was associated with reduced markers of joint stress and support for cartilage matrix integrity. Compositional analyses also show that eggshell membrane contains collagen types I and V, elastin, glycosaminoglycans, and bioactive matrix proteins, which are components relevant to connective tissue structure and function.*
These are the studies for Ovomet®. Below, we provided a summary of each key data for each study, along with a link to the complete clinical research.
- Summary of Study 1 – Full Study: https://www.openaccessjournals.com/articles/the-effect-of-daily-administration-of-300-mg-of-ovomet174-for-treatment-of-arthritis-in-elderly-patients.pdf
- Summary of Study 2 – Full Study: https://pubmed.ncbi.nlm.nih.gov/19340512/
- Summary of Study 3 – Full Study: https://www.hilarispublisher.com/abstract/effects-of-50-days-eggshell-membrane-ovomet174-supplementation-on-biomechanics-parameters-and-subjective-pain-perception-32226.html
- Summary of Study 4 – Full Study: https://www.longdom.org/open-access/effects-of-50-days-ovometsup174sup-supplementation-on-biomechanical-parameters-and-subjective-pain-perception-among-old--15750.html
- Summary of Study 5 – Full Study: https://www.longdom.org/open-access/shortterm-effects-of-ovometsup174sup-eggshell-membrane-in-joint-pain-a-doubleblind-and-placebo-study-17066.html
Ingredient Manufacturer Link: https://eggnovo.com/wellness-applications/nutraceutics/ovomet/
Study 1 Summary
Complete Study Information: https://www.openaccessjournals.com/articles/the-effect-of-daily-administration-of-300-mg-of-ovomet174-for-treatment-of-arthritis-in-elderly-patients.pdf
The Effect of Daily Administration of 300 mg of Ovomet® in Elderly Individuals Experiencing Joint Discomfort
Blasco et al. (2016). International Journal of Clinical Rheumatology, 11(5), 77.
This prospective clinical study evaluated daily supplementation with 300 mg of Ovomet® eggshell membrane in 20 older adults in their 70s experiencing age-related joint discomfort over a 50-day period, with assessments at days 10, 20, 30, and 50.
Study Design Highlights
- Study type: Prospective clinical study
- Participants: 20 older adults (70s) experiencing age-related joint discomfort
- Dose: 300 mg Ovomet® daily
- Duration: 50 days
- Assessment points: Days 10, 20, 30, and 50
Key Findings (What the Study Showed)
Joint Stiffness
- ↓ 10.6% by Day 10
- ↓ 58.3% by Day 50
Functional Capacity
- Improvements observed by Day 20
- ↑ 32.3% improvement in functional capacity by Day 50
Joint Comfort Measures
- Day 30: 50% of participants reported ≥20% improvement in joint comfort
- Day 50: 70% of participants reported ≥20% improvement in joint comfort
Overall Joint Condition
- 35.2% improvement in overall joint condition by study completion
Benefits of Ovomet® Demonstrated by This Study
Based directly on the study findings, Ovomet® at 300 mg/day was shown to:
✓ Support a 58.3% reduction in joint stiffness by day 50
✓ Support a 32.3% improvement in functional capacity by day 50
✓ Show early stiffness improvements beginning at day 10
✓ Support improvements in joint comfort in 70% of participants by day 50
✓ Support a 35.2% improvement in overall joint condition
Why This Study Matters
Daily supplementation with 300 mg of Ovomet® was associated with progressive improvements in measures of joint comfort, stiffness, and physical function over a 50-day period in older adults. Improvements beginning at day 10 and continuing through day 50 suggest both early and sustained support for joint mobility.*
Study 2 Summary
Complete Study Information: https://pubmed.ncbi.nlm.nih.gov/19340512/
Eggshell Membrane and Measures of Joint Comfort and Stiffness: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Clinical Study
Ruff et al. (2009). Clin Rheumatol. 2009 Aug;28(8):907-14.
This randomized, multicenter, double-blind, placebo-controlled clinical trial evaluated the effects of natural eggshell membrane (NEM®) supplementation (500 mg/day) in adults experiencing knee-related joint discomfort over 8 weeks, with assessments at 10, 30, and 60 days.
Study Design Highlights
- Study design: Randomized, multicenter, double-blind, placebo-controlled clinical trial
- Population: Adults experiencing knee-related joint discomfort
- Dose: 500 mg eggshell membrane (NEM®) daily
- Duration: 8 weeks (56 days)
- Assessment points: Days 10, 30, and 60
Key Findings (What the Study Showed)
Rapid Onset — Day 10
- Joint comfort improvement: ~18.4% vs. ~8.4% placebo
- Stiffness improvement: ~27.8% vs. ~7.6% placebo
Day 30
- Joint comfort improvement: ~31.3%
- Stiffness improvement: ~30.2%
Day 60 (End of Study)
- Joint comfort improvement: ~30–32%
- Stiffness improvement: ~32%
- All improvements were statistically significant compared with placebo
Benefits of Ovomet® Supported by This Study
Based directly on the clinical outcomes, eggshell membrane supplementation was shown to:
✓ Support statistically significant improvements in knee joint comfort vs. placebo
✓ Support statistically significant improvements in joint stiffness vs. placebo
✓ Demonstrate early onset of benefits within approximately 10 days
✓ Maintain progressive improvements through 8 weeks
Why This Study Matters
This randomized, placebo-controlled trial provides robust evidence that eggshell membrane supplementation can support joint comfort and stiffness measures in adults experiencing knee discomfort, with benefits emerging rapidly and continuing through 8 weeks.*
Reference Link: https://pubmed.ncbi.nlm.nih.gov/19340512/
Study 3 Summary
Complete Study Information: https://www.hilarispublisher.com/abstract/effects-of-50-days-eggshell-membrane-ovomet174-supplementation-on-biomechanics-parameters-and-subjective-pain-perception-32226.html
Effects of 50 Days Eggshell Membrane (Ovomet®) Supplementation on Biomechanics Parameters and Subjective Pain Perception in CrossFit Athletes
Aguirre et al. (2017). J Sports Med Doping Stud.
This randomized, double-blind, placebo-controlled study evaluated the effects of 50 days of Ovomet® (300 mg/day) in 22 CrossFit athletes, assessing joint comfort via WOMAC and EVA questionnaires alongside objective biomechanical measures including muscle strength, explosive power, and Achilles tendon stiffness via ultrasound.
Study Design Highlights
- Study design: Randomized, double-blind, placebo-controlled
- Participants: 22 CrossFit athletes
- Dose: 300 mg Ovomet® daily
- Duration: 50 days
Key Findings (What the Study Showed)
Joint Comfort (Subjective Measures)
- Ovomet® group: ~62.1% improvement in perceived joint comfort
- Placebo group: ~33.1% improvement
- Between-group differences were not statistically significant, though the magnitude favored the Ovomet® group
Achilles Tendon Stiffness (Ultrasound Measurement)
- Ovomet® group: Tendon stiffness maintained
- Placebo group: ~37.5% decrease in Achilles tendon stiffness
Muscle Strength & Explosive Power
- No statistically significant differences observed between groups
Benefits of Ovomet® Demonstrated by This Study
Based directly on the study findings, Ovomet® at 300 mg/day in CrossFit athletes was shown to:
✓ Support maintenance of Achilles tendon stiffness while placebo group experienced a ~37.5% decrease
✓ Support a greater magnitude of perceived joint comfort improvement (62.1% vs. 33.1% placebo)
✓ Demonstrate connective tissue resilience support during high-intensity repeated training
Why This Study Matters
The maintenance of Achilles tendon stiffness in the Ovomet® group — while the placebo group experienced a measurable decline — is a notable finding for individuals engaged in high-intensity training. Tendon stiffness can naturally decrease with repetitive mechanical stress, making this outcome relevant for supporting connective tissue resilience during periods of repeated physical loading.*
Study 4 Summary
Complete Study Information: https://www.longdom.org/open-access/effects-of-50-days-ovometsup174sup-supplementation-on-biomechanical-parameters-and-subjective-pain-perception-among-old--15750.html
Effects of 50 Days Ovomet® Supplementation on Biomechanical Parameters and Subjective Pain Perception among Old Institutionalized Patients: A Preliminary Study
Aguirre et al. (2017).
This randomized, double-blind, placebo-controlled preliminary study evaluated 300 mg/day Ovomet® over 50 days in 38 elderly institutionalized individuals (mean age ~85 years; 19 Ovomet®, 19 placebo), assessing joint comfort via the WOMAC questionnaire and Achilles tendon stiffness via ultrasound elastography.
Study Design Highlights
- Study design: Randomized, double-blind, placebo-controlled preliminary study
- Participants: 38 elderly institutionalized individuals (~85 ± 5 years)
- Dose: 300 mg Ovomet® daily
- Duration: 50 days
Key Findings (What the Study Showed)
WOMAC Composite Score (Joint Comfort, Stiffness, Function)
- Ovomet® group: ~40% improvement
- Placebo group: ~28% improvement
- Represents additional improvement beyond placebo
Achilles Tendon Linear Stiffness (Ultrasound)
- Ovomet® group: 46.5% increase in tendon stiffness
- Placebo group: Decrease in stiffness
Benefits of Ovomet® Demonstrated by This Study
Based directly on the study findings, Ovomet® at 300 mg/day in elderly individuals was shown to:
✓ Support a ~40% improvement in WOMAC composite score vs. ~28% placebo
✓ Support a 46.5% increase in Achilles tendon stiffness vs. placebo decline
✓ Demonstrate connective tissue and joint comfort support even in advanced age (~85 years)
✓ Produce biomechanical improvements measurable via ultrasound elastography
Why This Study Matters
Tendon stiffness often declines with age and reduced mobility, making the 46.5% increase in Achilles tendon stiffness in this population a particularly meaningful finding. These results suggest Ovomet® may help support connective tissue integrity and mobility in aging populations, with practical relevance for gait stability and functional movement capacity.*
Study 5 Summary
Complete Study Information: https://www.longdom.org/open-access/shortterm-effects-of-ovometsup174sup-eggshell-membrane-in-joint-pain-a-doubleblind-and-placebo-study-17066.html
Short-Term Effects of Ovomet® Eggshell Membrane on Measures of Joint Comfort: A Double-Blind and Placebo-Controlled Study
Gil-Quintana et al. (2018). J Arthritis. 2018;7:208.
This randomized, double-blind, placebo-controlled clinical trial evaluated the short-term effects of 300 mg/day Ovomet® in 18 adults experiencing joint discomfort over 30 days, with assessments at days 0, 1, 3, 5, 7, and 30 to capture both early onset and sustained improvements.
Study Design Highlights
- Study design: Randomized, double-blind, placebo-controlled
- Participants: 18 adults experiencing joint discomfort
- Dose: 300 mg Ovomet® daily
- Duration: 30 days
- Assessment points: Days 0, 1, 3, 5, 7, and 30
Key Findings (What the Study Showed)
Joint Comfort (WOMAC Pain Subscale)
- Statistically significant improvement beginning Day 3
- By Day 30: ~52% improvement in joint comfort scores
- Placebo: minimal change
Physical Function (WOMAC Function Subscale)
- Statistically significant improvement beginning Day 3
- By Day 30: ~48% improvement in physical function scores
- Placebo: minimal change
Benefits of Ovomet® Demonstrated by This Study
Based directly on the clinical outcomes, Ovomet® at 300 mg/day was shown to:
✓ Support statistically significant improvements in joint comfort as early as Day 3
✓ Support ~52% improvement in WOMAC joint comfort scores by Day 30
✓ Support ~48% improvement in WOMAC physical function scores by Day 30
✓ Demonstrate progressive improvements from Day 3 through Day 30
✓ Show minimal change in placebo group, highlighting the treatment effect
Why This Study Matters
This study highlights the potential for relatively rapid improvements in joint comfort — beginning at day 3 — with consistent Ovomet® supplementation. Early improvements may support adherence to continued use, while the ~52% and ~48% functional improvements by day 30 represent meaningful gains in joint comfort and everyday physical function.*
Big-Picture Integration with Other Studies
- Study 1: A prospective 50-day study in elderly adults experiencing joint discomfort found that daily supplementation with 300 mg Ovomet® was associated with improvements in joint stiffness (58.3% by day 50), functional capacity (32.3%), and overall joint condition (35.2%).
- Study 2: In an 8-week randomized, double-blind, placebo-controlled trial, 500 mg/day eggshell membrane was associated with statistically significant improvements in measures of knee joint comfort (~30–32%) and stiffness (~32%) compared to placebo, with onset within 10 days.
- Study 3: In a 50-day randomized, double-blind, placebo-controlled trial in CrossFit athletes, 300 mg/day Ovomet® was associated with maintenance of Achilles tendon stiffness (vs. ~37.5% decrease in placebo) and greater perceived joint comfort improvements.
- Study 4: In a 50-day randomized, double-blind, placebo-controlled study in elderly institutionalized individuals (~85 years), 300 mg/day Ovomet® was associated with ~40% WOMAC improvement vs. ~28% placebo and a 46.5% increase in Achilles tendon stiffness.
- Study 5: In a 30-day randomized, double-blind, placebo-controlled study, 300 mg/day Ovomet® was associated with ~52% improvement in joint comfort scores and ~48% improvement in physical function, with statistically significant changes observed as early as Day 3.
Ovomet® Ingredient Summary & Real-World Relevance
Taken together, the clinical evidence positions Ovomet® as a multi-component ingredient designed to support joint and connective tissue health. As a natural source of collagen types I, V, and X, elastin, glycosaminoglycans, and bioactive matrix proteins, Ovomet® provides nutrients that are relevant to connective tissue structure and function. Clinical studies have reported improvements in measures of joint comfort, mobility, and tendon biomechanics in both older adults and physically active populations.*
In practical terms, these findings suggest that consistent supplementation with Ovomet® may help support comfortable movement, mobility during daily activities, and connective tissue resilience across a range of ages and activity levels.*
Ingredient Manufacturer Link: https://eggnovo.com/wellness-applications/nutraceutics/ovomet/
Ovomet® is a clinically studied ingredient used in the following Silver Fern™ Brand product:
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.